Physician profile
Thomas J Berry
NPI 1629243431
$20,959.80
in general payments reported to CMS, 2019-2025
53 companies · $4,490 in 2025
The $4,490 reported for 2025 was more than what 90% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $245 · 2021: $4,204 · 2022: $2,885 · 2023: $5,431 · 2024: $2,956 · 2025: $4,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,922 · Travel and Lodging: $4,343 · Consulting Fee: $3,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,922.08 |
| Travel and Lodging | $4,342.63 |
| Consulting Fee | $3,612.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $3,703.14 | 2021-2023 | Intracept |
| Novartis Pharmaceuticals Corporation | $3,650.88 | 2025 | |
| Saluda Medical Americas, INC. | $3,347.80 | 2019-2025 | Evoke, Evoke Scs |
| Abbott Laboratories | $1,690.49 | 2021-2025 | Eterna, Proclaim |
| Spinal Simplicity, LLC | $1,668.96 | 2021-2025 | Ha Minuteman G3-R |
| Boston Scientific Corporation | $1,638.21 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Na |
| Pacira Pharmaceuticals Incorporated | $827.08 | 2021 | |
| Nalu Medical, INC. | $631.69 | 2022-2024 | Nalu Neurostimulation System |
| Spr Therapeutics, INC | $445.19 | 2022-2025 | Sprint Pns System |
| Foundation Fusion Solutions, LLC | $318.12 | 2023 | |
| Arbor Pharmaceuticals, INC. | $232.28 | 2019-2022 | |
| Ucb, INC. | $199.15 | 2019-2025 | Zilbrysq |
| Almatica Pharma LLC | $182.14 | 2021-2023 | Gralise |
| Medtronic, INC. | $166.01 | 2021-2025 | Synchromedii, Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Abbvie INC. | $154.69 | 2021-2023 | Ubrelvy, Qulipta |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $147.56 | 2019-2024 | Senza |
| Horizon Therapeutics Plc | $131.03 | 2019-2020 | |
| Genzyme Corporation | $121.81 | 2021-2023 | |
| Scilex Pharmaceuticals INC. | $112.14 | 2019-2020 | |
| Vertos Medical, INC. | $109.80 | 2021-2024 | Mild Device Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.09 | 2019-2021 | |
| Argenx US, INC. | $96.69 | 2022-2025 | Vyvgart Hytrulo |
| Pfizer INC. | $93.25 | 2023-2025 | |
| Biogen, INC. | $92.98 | 2019-2025 | Leqembi |
| Teva Pharmaceuticals USA, INC. | $84.57 | 2022-2023 | Austedo Xr, Austedo |
| Lilly USA, LLC | $84.42 | 2019-2023 | Emgality, Reyvow |
| Biotronik Nro, INC. | $82.56 | 2025 | Prospera |
| Medtronic USA, INC. | $80.45 | 2019-2020 | |
| Amgen INC. | $61.19 | 2019-2020 | |
| Acorda Therapeutics, INC | $58.23 | 2021 | |
| Collegium Pharmaceutical, INC. | $57.05 | 2023 | Belbuca |
| Pacira Therapeutics, INC. | $56.14 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $55.45 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.28 | 2019-2023 | Gammagard |
| Avanos Medical | $43.18 | 2019 | |
| Neurocrine Biosciences, INC. | $42.89 | 2019-2025 | |
| Eisai INC. | $36.00 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $29.57 | 2019-2020 | |
| Atland Pharmaceuticals, LLC | $28.92 | 2025 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Tanabe Pharma America, INC. | $25.40 | 2025 | Radicava |
| Painteq LLC | $23.25 | 2024 | Painteq |
| Globus Medical, INC. | $21.30 | 2025 | Omnia |
| Curonix LLC | $20.29 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Valinor Pharma, LLC | $20.15 | 2025 | Movantik |
| Janssen Biotech, INC. | $19.87 | 2025 | |
| Virtus Pharmaceuticals LLC | $18.37 | 2024 | Levorphanol Tartrate |
| Grifols USA, LLC | $14.73 | 2021 | |
| Pernix Therapeutics Holdings, INC. | $13.72 | 2019 | |
| Upsher-Smith Laboratories LLC | $13.66 | 2021 | |
| Biodelivery Sciences International, INC. | $13.43 | 2020 | |
| Vertiflex, INC. | $12.98 | 2019 | |
| Alnylam Pharmaceuticals INC. | $12.77 | 2021 | |
| Stimwave Technologies Incorporated | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$259.68 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.